SkinHealth Systems (SKIN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Jul, 2026Executive summary
Special Meeting scheduled for September 22, 2026, to be held virtually for all stockholders of record as of August 3, 2026.
Two proposals up for vote: a reverse stock split amendment and potential adjournment if quorum or votes are insufficient.
Board recommends voting in favor of both proposals to maintain Nasdaq listing and provide flexibility.
Proxy materials are available online, with voting accessible by internet, phone, or mail.
Voting matters and shareholder proposals
Proposal 1: Approve an amendment for a reverse stock split of Class A Common Stock at a ratio between 1-for-5 and 1-for-20, ratio to be set by the board within one year.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes or establish a quorum.
Board unanimously recommends voting FOR both proposals.
Stockholders can submit proposals for the 2027 annual meeting by December 25, 2026, and must comply with SEC and bylaw requirements.
Board of directors and corporate governance
Board retains discretion to set the reverse split ratio and to abandon the split if deemed not in the best interest of stockholders.
Proxy solicitation may be assisted by a firm, with estimated fees up to $20,000 plus expenses.
Board members and executive officers have interests only as stockholders.
Latest events from SkinHealth Systems
- Shareholders to vote on a reverse stock split and possible meeting adjournment on Sept 22, 2026.SKIN
Proxy filing - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SKIN
Proxy filing - Q2 2026 sales fell 7.8%, but margins and EBITDA improved amid ongoing market challenges.SKIN
Q2 2026 - Director elections, auditor ratification, and executive pay were addressed; no questions submitted.SKIN
AGM 2026 - Adjusted EBITDA rose to $8.5M as sales fell and guidance was lowered amid market headwinds.SKIN
Q1 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.SKIN
Proxy filing - Margins and profitability improved in 2025, with stable outlook and growth expected in 2027.SKIN
Q4 2025 - Gross margin rebounded to 51.6% in Q3 2024 despite a 19.1% sales decline.SKIN
Q3 2024 - Net sales dropped 22.9% as device sales lagged, prompting a downward revision to 2024 guidance.SKIN
Q2 2024